SurfaceLogix

Purchased by Nano Terra Inc. in 2011, Surface Logix Inc. works to create new small molecule drugs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. Using a proprietary chemistry platform, the group develops drugs that create New Chemical Entities (NCEs) which respond dynamically to the various physiological microenvironments in the human body. By enhancing molecular functionality, they are able to solve pharmacokinetic (PK) and pharmacodynamic (PD) problems not addressable with traditional medicinal chemistry practices.